This cluster covers the GLP-1 sourcing questions that serious buyers keep running into: who the supplier really is, whether COAs are plausible, whether purity claims hold up, and when shipping or storage risk justifies deeper verification.
You are evaluating semaglutide, tirzepatide, or retatrutide suppliers and need a buyer-side path before a meaningful order or deposit moves.
These pages are procurement-focused. They are about supplier qualification and sourcing risk, not medical use or dosing.